Piper Sandler analyst Christopher Raymond raised the firm’s price target on Regeneron to $956 from $895 and keeps an Overweight rating on the shares. Q4 U.S. Eylea franchise sales missed consensus estimates, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron, Sanofi announce U.S. FDA updated the label for Dupixent
- Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
- Twilio upgraded, Nutrien downgraded: Wall Street’s top analyst calls
- Regeneron upgraded to Outperform at RBC Capital on increased visibility
- Regeneron upgraded to Outperform from Sector Perform at RBC Capital